Skip to main content
NCBI home page
Experimental and Therapeutic Medicine logoLink to Experimental and Therapeutic Medicine
. 2018 Mar 6;15(5):4550–4556. doi: 10.3892/etm.2018.5927

Aberrant expression of miR-663 and transforming growth factor-β1 in nasal polyposis in children

Hailing Yu 1,✉, Jianbao Ju 2, Jingdong Liu 3, Da Li 1
PMCID: PMC5962837  PMID: 29849780

Abstract

The aim of the present study was to investigate the expression of microRNA (miR)-663 and its regulatory effects on the pathogenesis of nasal polyposis in children. Nasal polyp tissue, as well as serum and peripheral blood eosinophils were collected from 35 children diagnosed with nasal polypectomy between August 2013 and August 2015. As a control, the inferior nasal concha, serum and peripheral blood eosinophils were collected from 46 patients with nasal septal deviation complicated by inferior turbinate hypertrophy or patients with simple inferior turbinate hypertrophy who had undergone surgical removal of the inferior nasal concha. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to measure the expression of miR-663 and transforming growth factor-β1 (TGF-β1) in the nasal polyp tissue, serum and peripheral blood eosinophils of patients with nasal polyposis and controls. Western blotting was used to measure the expression of TGF-β1 protein in nasal tissue and eosinophils and an enzyme-linked immunosorbent assay was used to measure serum level of TGF-β1 protein. A dual luciferase reporter assay was used to determine whether TGF-β1 was a target gene of miR-663. Compared with the control group, levels of TGF-β1 mRNA and protein were significantly increased in all three types of specimens from pediatric patients with nasal polyposis (P<0.05). miR-663 expression was significantly decreased in nasal polyp tissue and peripheral blood eosinophils (P<0.05). The dual luciferase reporter assay confirmed that TGF-β1 was a target gene of miR-663. The current study suggests that the upregulation of TGF-β1 may be associated with the downregulation of miR-663 in nasal polyposis in children. miR-663 may have regulatory effects on the pathogenesis of nasal polyposis by regulating TGF-β1 and may be developed as a genetic marker of nasal polyposis in children.

Keywords: nasal polyposis, microRNA-663, transforming growth factor-β1, eosinophils

Introduction

Nasal polyps are chronic inflammatory lesions located in the nasal cavity or sinus mucosa. Previous studies have classified nasal polyposis as a subtype or progressive stage of chronic sinusitis (1–3). Epidemiological surveys demonstrated that 2–4% of the global population was affected by nasal polyposis in 2003 (4–6). Nasal polyposis poses a threat to the health and quality of life of patients, particularly in pediatric patients (7,8). Nasal polyposis in pediatric patients may induce constriction of the nasal cavity and nasal meatus, which may cause difficulties in postoperative cleanup and increase the susceptibility of patients to respiratory infections (9).

Among the three isoforms of transforming growth factor β (TGF-β), TGF-β1 is the isoform predominantly expressed in nasal polyposis (10). TGF-β1 primarily originates from inflammatory cells, including eosinophils, macrophages and epithelial cells (11). TGF-β1 serves a key role in cell biological behaviors, including extracellular matrix formation and fibrosis, epithelial cell metaplasia, vascularization, immune hypersensitivity, embryonic development, cell senescence and apoptosis (12). Among these functions, promoting the formation of the extracellular matrix is the most prominent feature of TGF-β1 (13,14). TGF-β1 is one of the important signaling molecules secreted by inflammatory cells during inflammation (15,16). However, the role of TGF-β1 in the inflammation and regulatory mechanisms of pathogenesis in nasal polyposis in children remains unknown. It has been reported that microRNA-663 (miR-663) is an upstream regulator of TGF-β1 and inhibits the development of papillary thyroid carcinoma and liver cancer through regulating TGF-β1 (17–18). However, whether miR-663 regulates TGF-β1 in nasal polyposis of children is unknown.

The aim of the present study was to measure the expression of TGF-β1 mRNA and protein in nasal polyp tissue, serum and peripheral blood eosinophils using reverse transcription-quantitative polymerase chain reaction, western blotting, bioinformatics prediction analysis and ELISA in pediatric patients with nasal polyposis. Additionally, the association between the expression of TGF-β1 and miR-663 was verified in order to evaluate their roles in the pathogenesis of nasal polyposis in children.

Patients and methods

Participant recruitment and selection criteria

Nasal polyp tissue, serum and peripheral blood eosinophils were collected from 35 pediatric patients with nasal polyposis who had undergone nasal polypectomy in the Department of Otolaryngology in the Women and Children's Hospital of Qingdao (Qingdao, China) between August 2013 and August 2015. These patients were part of the patient group and there were 16 males and 19 females with a median age of 11 years (age range, 7–14 years). The inclusion criteria and exclusion criteria for patients were as previously described (19). The diagnosis of nasal polyposis in all patients was confirmed by pathologists. The inferior nasal concha, serum and peripheral blood eosinophils were collected from 46 patients with nasal septal deviation complicated by inferior turbinate hypertrophy or patients with simple inferior turbinate hypertrophy undergoing surgical removal of inferior nasal concha. These patients were part of the control group and there were 18 males and 28 females with a median age of 10 years (age range, 6–14 years). Patients in the two groups were excluded if they were diagnosed with infection, diabetes, cancer, or autoimmune disease, or exhibited complications involving the heart, liver and kidney. Prior written informed consent was obtained from the patients' families and the present study was approved by the Ethics Review Board of the Women and Children's Hospital of Qingdao (Qingdao, China).

Reagents and antibodies

The miRcute miRNA Isolation kit, miRcute miRNA cDNA first strand synthesis kit, miRcute miRNA quantitative fluorescence detection kit (FP401), SuperReal PreMix (SYBR Green; FP204) and TIANScript II cDNA first strand synthesis kit (KR107) were all purchased from Tiangen Biotech Co., Ltd. (Beijing, China). The rabbit anti-human TGF-β1 antibody (ab92486) and rabbit anti-human β-actin antibody (ab6276) were purchased from Abcam (Cambridge, MA, USA). TRIzol reagent (10606ES60; Shanghai YISHENG Biology Technology Co., Ltd., Shanghai, China), goat anti-rabbit secondary antibody (ab6721; Abcam), BCA Protein assay kit (RTP7102, Beijing Zhongke Ruitai, Beijing, China) and serum RNA extraction kit miRNeasy Serum/Plasma kit (JL217184; Guangzhou Jianlun Biological Technology Co., Ltd., Guangzhou, China) were also used in the current study. A TGF-β1 ELISA kit (ab100674; Abcam), enhanced chemiluminence (ECL) solution (FDO0142; Nanjing Aoduofuni Biotechnology Co., Ltd., Nanjing, China), miR-663 mimics (Guangzhou Ruibo Biological Technology Co., Ltd., Guangzhou, China) were purchased. Anti-cluster of differentiation (CD)16 immunomagnetic beads (YB-22355) were purchased from Yubo Biological Technology Co., Ltd., (Shanghai, China). Ficoll-Hypaque separation medium (Cedarlane Laboratories, Burlington, Canada) including Solution A (12%, density: 1.090), Solution B (9.0%, density: 1.076) and Solution C (6.4%, density: 1.065) was also used in the current study.

Specimen collection

Nasal polyp tissues were collected during surgery and frozen in liquid nitrogen. Peripheral blood was collected from all patients and stored at −20°C and the serum was isolated by centrifugation at 400 × g for 10 min at 4°C. Peripheral blood eosinophils were isolated using Magnetic activated cell sorting (MACS). Peripheral blood (100 µl) was collected and EDTA anticoagulant (0.1 mol/l, pH 7.7) and a specific dye for eosinophils (0.9 ml) were added. Eosinophils were then counted using an ECLIPSE TS100 (Nikon Corporation, Tokyo, Japan) at a magnification of ×100. The remaining blood was diluted with 6% dextran (1:5) and placed in a water bath at 37°C for 40 min. The supernatant was centrifuged at 600 × g at room temperature for 10 min and the leukocyte specimen was collected. Subsequently, the leukocyte specimen was mixed with solutions A, B and C of the Ficoll-Hypaque separation medium and centrifuged at 800 × g for 20 min at room temperature. Cell suspensions were divided into four layers and the eosinophil layer was aspirated and washed twice with PBS (0.01 mol/l). The total number of cells including eosinophils was counted using an ECLIPSE TS100 (Nikon Corporation). Four fields under ×100 magnification were randomly selected for cell counting. Anti-CD16 MicroBeads (20 µl, pre-cooled at 4°C) were added to 1×107 total cells, mixed well and incubated at 6–12°C for 15 min. The cell mixture was applied twice to the MACS column (Miltenyibiotec, Bergisch Gladbach, Germany). The magnetically anti-CD16 labeled cells (neutrophils) were arrested in the separation column while unlabeled cells (eosinophils) passed through the column. Isolated eosinophils were collected and washed with PBS (0.01 mol/l). Cells were incubated in an atmosphere containing 5% CO2 at 37°C. The eosinophils were counted at every step and stained with Trypan blue at room temperature for 3 min to evaluate cell activity.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Frozen tissues (pulverized in liquid nitrogen) were lysed thoroughly using 1 ml TRIzol reagent and total RNA was extracted using the phenol chloroform method (20). Total RNA was extracted using the serum RNA extraction kit miRNeasy Serum/Plasma kit. Gel electrophoresis and spectrophotometry were conducted to measure the optical density (OD) 260/280 ratio and measure the concentration and quality of RNA. Total RNA (1 µg) was reverse transcribed into cDNA using the TIANScript II cDNA first strand synthesis kit according to the manufacturer's protocols. The SuperReal PreMix (SYBR Green) was used during qPCR with the following primers: TGF-β1, forward, 5′-GGACACCAACTATTGCTTCAG-3′ 160 base pairs (bp) and reverse, 5′-TCCAGACTCCAAATGTAG-3′; β-actin, forward, 5′-TTCCAGCCTTCCTTCCTGG-3′ 224 bp and reverse, 5′-TTGCGCTCAGGAGGAGGAAT-3′. The reaction conditions of qPCR were as follows: Pre-denaturation at 95°C for 2 min, 30 cycles of denaturation at 94°C for 45 sec, annealing at 55°C for 55 sec, extension at 72°C for 1 min and a final cycle at 72°C for 10 min. Relative quantification of TGF-β1 was calculated as the ratio of TGF-β1/β-actin using the 2−ΔΔCq method (21).

The miRcute miRNA Isolation kit was used to isolate miR-663 from cells. An miRcute miRNA cDNA first strand synthesis kit was used to obtain cDNA. To detect miR-663, the miRcute miRNA quantitative fluorescence detection kit was used and U6 was the internal control. The primers used were as follows: U6, forward, 5′-CTCGCTTCGGCAGCACA-3′ and reverse, 5′-AACGCTTCACGAATTTGCGT-3′; miR-663, forward, 5′-TGCGGAGGCGGGGCGCCGCGGG-3′ and reverse, 5′-CCAGTGCAGGGTCCGAGGT-3′. The reaction conditions were as follows: Pre-denaturation at 95°C for 3 min, 40 cycles of denaturation at 94°C for 30 sec, annealing at 56°C for 30 sec and extension at 72°C for 20 sec. The ratio of miR-663/U6 was calculated using the 2−ΔΔCq method (21).

Western blotting

The total proteins were extracted using a protein extraction kit (310003; BestBio Company, Shanghai, China) following the manufacturers' instructions. The concentration of protein was measured using the BCA protein assay kit. Protein samples (30 µg/lane) were analyzed using 10% SDS-polyacrylamide gel electrophoresis and transferred to a PVDF membrane. The membrane was then blocked with 5% non-fat milk for 1 h at room temperature. Primary antibodies against TGF-β1 (1:500) and β-actin (1:5,000) were added and incubated at 4°C overnight. Goat anti-rabbit secondary antibody (1:3,000; cat no. ab6721; Abcam) were added and incubated at room temperature for 1 h. The PVDF membrane was placed in the ECL detection system and imaged using Image Lab Software version 3.0 (Bio-Rad Laboratories, Inc., Hercules, CA, USA) to acquire and analyze imaging signals of protein bands. The relative density of target protein was defined as the ratio of gray values between the target protein and β-actin.

ELISA

The TGF-β1 ELISA kit was used to perform ELISA. ELISA plates were classified into standard, serum and blank wells. Standard samples (50 µl) and serum (10 and 40 µl sample diluent) were added to the wells, whereas no solution was added to blank wells. Subsequently, horseradish peroxidase-labeled goat anti-rabbit secondary antibody (cat no. ab6721; Abcam; 100 µl) was added to each well and incubated at 37°C for 1 h. The plates were then washed 5 times and substrates A (50 µl) and B (50 µl), respectively, were added. Following incubation for 15 min at 37°C, stop solution (50 µl) was added. The absorbance value at OD 450 nm was measured within 15 min on the Multiskan FC microplate reader (Thermo Scientific Inc., Waltham, MA, USA).

Bioinformatics predictions of upstream-regulatory miR for TGF-β1

Bioinformatics prediction is one of the major approaches for functional studies of miR. To further determine the regulatory mechanism of upstream miRs in the pathogenesis of nasal polyposis, target gene prediction software, including miRanda (http://www.microma.org/rnicroma/home.do), TargetScan 2.0 (www.targetscan.org) and PicTar (http://pictar.mdc-berlin.de/) were used to identify the potential genes that have regulatory effects on TGF-β1. The procedures were performed according to the instructions on each website.

Dual-luciferase reporter assay

The wild-type and mutant type 3′-untranslated region (UTR) in TGF-β1 were chemically synthesized in vitro. The wild-type and mutant type 3′-UTR were added to the restriction enzyme cleavage sites of SpeI and HindIII and cloned into a pMIR-REPORT luciferase reporter plasmid (cat no. AM5795; Ambion; Thermo Fisher Scientific, Inc.). 293T cells (Cobioer Biosciences Co., Ltd., Nanjing, China) were co-transfected with plasmid with wild type 3′-UTR (0.8 µg) and miR-663 mimics (100 nM), or co-transfected with mutant type 3′-UTR (0.8 µg) and miR-663 mimics (100 nM) (synthesized by Sangon Biotech Co., Ltd., Shanghai, China). 293T cells transfected with empty plasmid were considered to be negative controls. Cells were incubated at 37°C for 24 h and then lysed. Fluorescence was measured using a GloMax® 20/20 luminometer according to the instructions of the dual luciferase reporter system kit (Promega Corporation, Madison, WI, USA). Renilla fluorescent activity was considered as an internal reference.

Statistical analysis

All data were analyzed using SPSS 18.0 software (SPSS, Inc., Chicago, IL, USA). Measurement data were expressed as mean ± standard deviation. Normality tests were conducted for all data and a T test was used for comparison between two independent groups. One-way analysis of variance (ANOVA) was used to compare data of more than two independent groups. For data with homogeneity of variance, least significant difference and Student-Newman-Keuls methods were used following ANOVA; otherwise, Tamhane's T2 or Dunnett's T3 method was used. P<0.05 was considered to indicate a statistically significant difference.

Results

mRNA expression of TGF-β1 in different specimens

RT-qPCR was performed to detect the expression of TGF-β1 mRNA in different specimens. The results demonstrated that, compared with controls, the expression of TGF-β1 mRNA was significantly upregulated in nasal polyp tissue (P<0.01; Fig. 1A), serum (P<0.05; Fig. 1B) and peripheral blood eosinophils (P<0.01; Fig. 1C) of pediatric patients with nasal polyposis. These results indicate that TGF-β1 may serve an important role in the pathogenesis of nasal polyposis in children.

Figure 1.

Figure 1.

Open in a new tab

Analysis of TGF-β1 mRNA expression. The expression of TGF-β1 mRNA in (A) nasal polyp tissue, (B) serum and (C) peripheral blood eosinophils was measured using reverse transcription-quantitative polymerase chain reaction. All data are presented as the mean + standard deviation. *P<0.05 and **P<0.01 vs. Control. NP, patients with nasal polyposis; TGF-β1, transforming growth factor-β1.

Expression of TGF-β1 protein in nasal polyp tissue and eosinophils

Western blotting was performed to detect the expression of TGF-β1 protein in nasal polyp tissue and peripheral blood eosinophils. The results demonstrated that, compared with controls, expression of TGF-β1 was significantly upregulated in the nasal polyp tissue (Fig. 2A) and peripheral blood eosinophils (P<0.01; Fig. 2B) of pediatric patients with nasal polyposis. To confirm these results, TGF-β1 levels in serum were measured using ELISA. Compared with controls, levels of TGF-β1 protein were significantly upregulated in the serum of pediatric patients with nasal polyposis (P<0.05; Fig. 2C). These results suggest that changes in the expression of TGF-β1 protein are positively associated with changes in the expression of TGF-β1 mRNA. Thus, upregulated TGF-β1 levels may have regulatory effects on the pathogenesis of nasal polyposis in children.

Figure 2.

Figure 2.

Open in a new tab

Analysis of TGF-β1 protein expression. The expression of TGF-β1 in (A) nasal polyp tissue and (B) peripheral blood eosinophils was measured by western blotting. The protein expression of TGF-β1 in (C) serum was measured using ELISA. Data are presented as the mean + standard deviation. *P<0.05 and **P<0.01 vs. Control. TGF-β1, transforming growth factor-β1; NP, patients with nasal polyposis.

Expression of miR-663 expression in different specimens

To detect the level of miR-663 in nasal polyp tissue, serum and peripheral blood eosinophils of pediatric patients with nasal polyposis, RT-qPCR was performed. As presented in Fig. 3, the expression of miR-663 was significantly decreased in the nasal polyp tissue (P<0.05; Fig. 3A) and peripheral blood eosinophils (P<0.01; Fig. 3C) of pediatric patients with nasal polyposis compared with controls. However, there was no significant difference in miR-663 expression in the serum of patients with nasal polyposis compared with controls (P>0.05; Fig. 3B). These results suggest that miR-663 may serve a role in the pathogenesis of nasal polyposis.

Figure 3.

Figure 3.

Open in a new tab

Analysis of miR-663 expression. miR-663 expression in (A) nasal polyp tissue, (B) serum and (C) peripheral blood eosinophils was detected using reverse transcription-quantitative polymerase chain reaction. All data are presented as the mean + standard deviation. *P<0.05 and **P<0.01 vs. Control. NP, patients with nasal polyposis; miR-663, microRNA-663.

Dual-luciferase reporter assay

To identify whether TGF-β1 is a target of miR-663, a bioinformatics prediction was conducted. It was determined that miR-663 is one of the regulatory genes for TGF-β1 and the binding sequence is presented (Fig. 4A). A dual-luciferase reporter assay was conducted to verify this result. Following co-transfection with miR-663 mimics and wild-type 3′UTR, the fluorescence values decreased significantly (P<0.05; Fig. 4B). By contrast, there was no significant difference in the fluorescence value of the mutant group compared with the negative control (Fig. 4B). These findings suggest that miR-663 binds to the 3′-UTR of TGF-β1 to regulate TGF-β1 expression.

Figure 4.

Figure 4.

Open in a new tab

The regulating effects of miR-663 on the expression of TGF-β1. (A) Bioinformatics prediction result. (B) Result of dual-luciferase reporter assay. All data are presented as the mean + standard deviation. **P<0.01 vs. NC. TGF-β1, transforming growth factor-β1; NP, patients with nasal polyposis; NC, negative control; miR-663, microRNA-663; 3′UTR, 3′untranslated region.

Discussion

In the present study, the expression of TGF-β1 and its upstream gene miR-663 were detected in nasal polyp tissue, serum and peripheral blood eosinophils of children with nasal polyposis. A dual-luciferase reporter assay was performed to confirm the binding of miR-663 and TGF-β1 and to evaluate whether miR-663 contributes to the pathogenesis of nasal polyposis.

Nasal polyposis is a type of refractory rhinologic disease in children characterized by an unknown pathogenesis, persistent activity and difficulty of treatment (22). In the past, it was thought that nasal polyposis was caused by an allergic reaction (23). However, recent studies suggest that the clinical features of nasal polyposis are similar to those of eosinophilic non-allergic rhinitis (24,25). The concept of eosinophilic non-allergic rhinitis was proposed in 1979 and it was suggested that eosinophils may serve a key role in inflammation, similar to their role in chronic sinusitis. However, this hypothesis cannot explain the accumulation of eosinophils that occurs in nasal polyp tissue. Previous studies have investigated the mechanism of eosinophil accumulation in nasal polyposis (26–28), which emphasizes nasal polyps as the products of inflammatory reactions, regulated by cytokines in the local microenvironment. Nasal polyp cells, including epithelial cells and fibroblasts, can secrete cytokines that stimulate and prolong the cell cycle of inflammatory cells, particularly eosinophils (29). Furthermore, eosinophils themselves are able to synthesize and secrete important inflammatory cytokines and regulatory factors, which in turn can stimulate inflammatory cell proliferation (30).

TGF-β1 is produced by eosinophils. Studies have demonstrated that TGF-β1 promotes the production of interleukin (IL)-6 from human fibroblasts and the growth of fibroblasts and osteoblasts by regulating the transcription of IL-6 (31–33). TGF-β1 may promote the formation of the extracellular matrix and serve an important role in cell morphogenesis, proliferation and differentiation in muscle tissue (34–36). In vivo studies have demonstrated that the upregulation of TGF-β1 in local tissue can promote wound healing and the formation of typical granulation tissue (37). In the present study, TGF-β1 expression was upregulated in all specimens taken from pediatric patients with nasal polyposis. This upregulation may promote the proliferation of fibroblasts and the formation of typical granulation tissue; these effects are closely associated with the formation of nasal polyposis (38,39). Thus, TGF-β1 may promote the pathogenesis of nasal polyposis.

The regulation mechanism of TGF-β1 expression has not been fully elucidated. Studies have suggested that nemo-like kinase and Smad protein may be regulate TGF-β1 (40,41). In addition, specific miRs can negatively regulate the expression of TGF-β1 by cleaving TGF-β1 mRNA and inhibiting its translation. This inhibitory effect is important in maintaining the balance of the physiological and pathological states of the human body (42,43). Recent studies have demonstrated that TGF-β1 mRNA regulates miR in nasal polyposis and it was determined that miR-1343 may regulate the expression of TGF-β1 receptors (44–46). In the current study, bioinformatic predictions revealed that miR-663 is an upstream miR, which may have regulatory effects on TGF-β1 expression. The results also demonstrated that levels of miR-663 decrease following the upregulation of TGF-β1 mRNA and protein. Furthermore, the results of the dual-luciferase reporter assay determined that miR-663 contributes to the targeted regulation of TGF-β1 by binding to the 3′-UTR of TGF-β1 and ultimately impacts on the pathological features of nasal polyposis. However, in the current study, serum levels of miR-663 did not change markedly, even though levels of serum TGF-β1 increased. It was thus speculated that the elevation of TGF-β1 was primarily caused by the abundant release of inflammatory cells rather than the downregulation of miR-663.

In conclusion, the present study demonstrated that miR-663 serves important biological functions in the regulation of TGF-β1 gene expression and the onset and development of nasal polyposis. The results of the current study may therefore provide experimental evidence for the prevention and treatment of pediatric patients with nasal polyposis in clinical practice.

Acknowledgements

The present study was supported by a grant from the Natural Science Foundation of Shandong Province of China (grant no. ZR2013HM024).

References

  • 1.Bachert C, Zhang N, van Zele T, Gevaert P. Chronic rhinosinusitis: From one disease to different phenotypes. Pediatr Allergy Immunol. 2012;23(Suppl 22):S2–S4. doi: 10.1111/j.1399-3038.2012.01318.x. [DOI] [PubMed] [Google Scholar]
  • 2.Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, Hellings P, Jiao L, Wang L, Evans RR, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: A randomized clinical trial. JAMA. 2016;315:469–479. doi: 10.1001/jama.2015.19330. [DOI] [PubMed] [Google Scholar]
  • 3.Neubauer PD, Schwam ZG, Manes RP. Comparison of intranasal fluticasone spray, budesonide atomizer, and budesonide respules in patients with chronic rhinosinusitis with polyposis after endoscopic sinus surgery. Int Forum Allergy Rhinol. 2016;6:233–237. doi: 10.1002/alr.21688. [DOI] [PubMed] [Google Scholar]
  • 4.Johansson L, Akerlund A, Holmberg K, Melén I, Bende M. Prevalence of nasal polyps in adults: The Skövde population-based study. Ann Otol Rhinol Laryngol. 2003;112:625–629. doi: 10.1177/000348940311200709. [DOI] [PubMed] [Google Scholar]
  • 5.We J, Lee WH, Tan KL, Wee JH, Rhee CS, Lee CH, Ahn S, Lee JH, Kim JW. Prevalence of nasal polyps and its risk factors: Korean national health and nutrition examination survey 2009–2011. Am J Rhinol Allergy. 2015;29:e24–e28. doi: 10.2500/ajra.2015.29.4131. [DOI] [PubMed] [Google Scholar]
  • 6.Feng S, He Q, Fan Y, Mi J, Guo L, Hong H, Li H. Nasal endoscopic findings and nasal symptoms in patients with asthma: A clinical study from a rhinological perspective. Allergol Immunopathol (Madr) 2015;43:42–47. doi: 10.1016/j.aller.2013.10.005. [DOI] [PubMed] [Google Scholar]
  • 7.Fetta M, Tsilis NS, Segas JV, Nikolopoulos TP, Vlastarakos PV. Functional endoscopic sinus surgery improves the quality of life in children suffering from chronic rhinosinusitis with nasal polyps. Int J Pediatr Otorhinolaryngol. 2017;100:145–148. doi: 10.1016/j.ijporl.2017.06.007. [DOI] [PubMed] [Google Scholar]
  • 8.Weber SAT, Iyomasa RM, Correa CC, Florentino WNM, Ferrari GF. Nasal polyposis in cystic fibrosis: Follow-up of children and adolescents for a 3-year period. Braz J Otorhinolaryngol. 2017;83:677–682. doi: 10.1016/j.bjorl.2016.09.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Veloso-Teles R, Cerejeira R. Endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps: Clinical outcome and predictive factors of recurrence. Am J Rhinol Allergy. 2017;31:56–62. doi: 10.2500/ajra.2017.31.4402. [DOI] [PubMed] [Google Scholar]
  • 10.Park IH, Um JY, Hong SM, Cho JS, Lee SH, Lee SH, Lee HM. Metformin reduces TGF-β1-induced extracellular matrix production in nasal polyp-derived fibroblasts. Otolaryngol Head Neck Surg. 2014;150:148–153. doi: 10.1177/0194599813513880. [DOI] [PubMed] [Google Scholar]
  • 11.Piersma B, Bank RA, Boersema M. Signaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge. Front Med (Lausanne) 2015;2:59. doi: 10.3389/fmed.2015.00059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Castellone MD, Laukkanen MO. TGF-beta1, WNT, and SHH signaling in tumor progression and in fibrotic diseases. Front Biosci (Schol Ed) 2017;9:31–45. doi: 10.2741/s470. [DOI] [PubMed] [Google Scholar]
  • 13.Poniatowski LA, Wojdasiewicz P, Gasik R, Szukiewicz D. Transforming growth factor Beta family: Insight into the role of growth factors in regulation of fracture healing biology and potential clinical applications. Mediators Inflamm. 2015;2015:137823. doi: 10.1155/2015/137823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Vadon-Le Goff S, Hulmes DJ, Moali C. BMP-1/tolloid-like proteinases synchronize matrix assembly with growth factor activation to promote morphogenesis and tissue remodeling. Matrix Biol. 2015;44–46:14–23. doi: 10.1016/j.matbio.2015.02.006. [DOI] [PubMed] [Google Scholar]
  • 15.Richter K, Konzack A, Pihlajaniemi T, Heljasvaara R, Kietzmann T. Redox-fibrosis: Impact of TGFβ1 on ROS generators, mediators and functional consequences. Redox Biol. 2015;6:344–352. doi: 10.1016/j.redox.2015.08.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Lafyatis R. Transforming growth factor β-at the centre of systemic sclerosis. Nat Rev Rheumatol. 2014;10:706–719. doi: 10.1038/nrrheum.2014.137. [DOI] [PubMed] [Google Scholar]
  • 17.Huang Y, Liu J, Fan L, Wang F, Yu H, Wei W, Sun G. miR-663 overexpression induced by endoplasmic reticulum stress modulates hepatocellular carcinoma cell apoptosis via transforming growth factor beta 1. Onco Targets Ther. 2016;9:1623–1633. doi: 10.2147/OTT.S96902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wang Z, Zhang H, Zhang P, Dong W, He L. MicroRNA-663 suppresses cell invasion and migration by targeting transforming growth factor beta 1 in papillary thyroid carcinoma. Tumour Biol. 2016;37:7633–7644. doi: 10.1007/s13277-015-4653-y. [DOI] [PubMed] [Google Scholar]
  • 19.Fokkens W, Lund V, Mullol J. European Position Paper on Rhinosinusitis and Nasal Polyps Group: EP3OS 2007: European position paper on rhinosinusitis and nasal polyps 2007. A summary for otorhinolaryngologists. Rhinology. 2007;45:97–101. [PubMed] [Google Scholar]
  • 20.Qin JJ, Lu ZY, Jiao ZP, Zhu XJ, Wang YX, Tang H. Modified TRIzol method for RNA and DNA co-extraction from blood. Fa Yi Xue Za Zhi. 2013;29:209–211. (In Chinese) [PubMed] [Google Scholar]
  • 21.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
  • 22.Hulse KE, Stevens WW, Tan BK, Schleimer RP. Pathogenesis of nasal polyposis. Clin Exp Allergy. 2015;45:328–346. doi: 10.1111/cea.12472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Bernstein JM, Gorfien J, Noble B. Role of allergy in nasal polyposis: A review. Otolaryngol Head Neck Surg. 1995;113:724–732. doi: 10.1016/S0194-5998(95)70012-9. [DOI] [PubMed] [Google Scholar]
  • 24.Calus L, Devuyst L, Van Zele T, De Ruyck N, Derycke L, Bachert C, Gevaert P. The response to nasal allergen provocation with grass pollen is reduced in patients with chronic rhinosinusitis with nasal polyposis and grass sensitization. Clin Exp Allergy. 2016;46:555–563. doi: 10.1111/cea.12687. [DOI] [PubMed] [Google Scholar]
  • 25.Becker S, Rasp J, Eder K, Berghaus A, Kramer MF, Gröger M. Non-allergic rhinitis with eosinophilia syndrome is not associated with local production of specific IgE in nasal mucosa. Eur Arch Otorhinolaryngol. 2016;273:1469–1475. doi: 10.1007/s00405-015-3769-4. [DOI] [PubMed] [Google Scholar]
  • 26.Fokkens W, Lund V, Mullol J. European Position Paper on Rhinosinusitis and Nasal Polyps group: European position paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl. 2007;20:1–136. [PubMed] [Google Scholar]
  • 27.Fundová P, Funda DP, Kovar D, Holy R, Navara M, Tlaskalová-Hogenová H. Increased expression of chemokine receptors CCR1 and CCR3 in nasal polyps: Molecular basis for recruitment of the granulocyte infiltrate. Folia Microbiol (Praha) 2013;58:219–224. doi: 10.1007/s12223-012-0194-6. [DOI] [PubMed] [Google Scholar]
  • 28.De Corso E, Baroni S, Romitelli F, Luca L, Di Nardo W, Passali GC, Paludetti G. Nasal lavage CCL24 levels correlate with eosinophils trafficking and symptoms in chronic sino-nasal eosinophilic inflammation. Rhinology. 2011;49:174–179. doi: 10.4193/Rhino10.133. [DOI] [PubMed] [Google Scholar]
  • 29.Pawankar R, Nonaka M. Inflammatory mechanisms and remodeling in chronic rhinosinusitis and nasal polyps. Curr Allergy Asthma Rep. 2007;7:202–208. doi: 10.1007/s11882-007-0073-4. [DOI] [PubMed] [Google Scholar]
  • 30.Pawliczak R, Lewandowska-Polak A, Kowalski ML. Pathogenesis of nasal polyps: An update. Curr Allergy Asthma Rep. 2005;5:463–471. doi: 10.1007/s11882-005-0027-7. [DOI] [PubMed] [Google Scholar]
  • 31.Janda K, Krzanowski M, Dumnicka P, Kusnierz-Cabala B, Krasniak A, Sulowicz W. Transforming growth factor beta 1 as a risk factor for cardiovascular diseases in end-stage renal disease patients treated with peritoneal dialysis. Clin Lab. 2014;60:1163–1168. doi: 10.7754/Clin.Lab.2013.130337. [DOI] [PubMed] [Google Scholar]
  • 32.Jin X, Ren S, Macarak E, Rosenbloom J. Pathobiological mechanisms of peritoneal adhesions: The mesenchymal transition of rat peritoneal mesothelial cells induced by TGF-β1 and IL-6 requires activation of Erk1/2 and Smad2 linker region phosphorylation. Matrix Biol. 2016;51:55–64. doi: 10.1016/j.matbio.2016.01.017. [DOI] [PubMed] [Google Scholar]
  • 33.Xiao K, Jiao L, Cao S, Song Z, Hu C, Han X. Whey protein concentrate enhances intestinal integrity and influences transforming growth factor-β1 and mitogen-activated protein kinase signalling pathways in piglets after lipopolysaccharide challenge. Br J Nutr. 2016;115:984–993. doi: 10.1017/S0007114515005085. [DOI] [PubMed] [Google Scholar]
  • 34.Cicha I, Yilmaz A, Klein M, Raithel D, Brigstock DR, Daniel WG, Goppelt-Struebe M, Garlichs CD. Connective tissue growth factor is overexpressed in complicated atherosclerotic plaques and induces mononuclear cell chemotaxis in vitro. Arterioscler Thromb Vasc Biol. 2005;25:1008–1013. doi: 10.1161/01.ATV.0000162173.27682.7b. [DOI] [PubMed] [Google Scholar]
  • 35.Chen S, Liu J, Yang M, Lai W, Ye L, Chen J, Hou X, Ding H, Zhang W, Wu Y, et al. Fn14, a downstream target of the TGF-β signaling pathway, regulates fibroblast activation. PLoS One. 2015;10:e0143802. doi: 10.1371/journal.pone.0143802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Kanaan RA, Aldwaik M, Al-Hanbali OA. The role of connective tissue growth factor in skeletal growth and development. Med Sci Monit. 2006;12:RA277–RA281. [PubMed] [Google Scholar]
  • 37.Aström P, Pirilä E, Lithovius R, Heikkola H, Korpi JT, Hernández M, Sorsa T, Salo T. Matrix metalloproteinase-8 regulates transforming growth factor-β1 levels in mouse tongue wounds and fibroblasts in vitro. Exp Cell Res. 2014;328:217–227. doi: 10.1016/j.yexcr.2014.07.010. [DOI] [PubMed] [Google Scholar]
  • 38.Park SK, Jin YD, Park YK, Yeon SH, Xu J, Han RN, Rha KS, Kim YM. IL-25-induced activation of nasal fibroblast and its association with the remodeling of chronic rhinosinusitis with nasal polyposis. PLoS One. 2017;12:e0181806. doi: 10.1371/journal.pone.0181806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Shin JM, Park JH, Kang B, Lee SA, Park IH, Lee HM. Effect of doxycycline on transforming growth factor-beta-1-induced matrix metalloproteinase 2 expression, migration, and collagen contraction in nasal polyp-derived fibroblasts. Am J Rhinol Allergy. 2016;30:385–390. doi: 10.2500/ajra.2016.30.4381. [DOI] [PubMed] [Google Scholar]
  • 40.Xiao Z, Zhang J, Peng X, Dong Y, Jia L, Li H, Du J. The Notch γ-secretase inhibitor ameliorates kidney fibrosis via inhibition of TGF-β/Smad2/3 signaling pathway activation. Int J Biochem Cell Biol. 2014;55:65–71. doi: 10.1016/j.biocel.2014.08.009. [DOI] [PubMed] [Google Scholar]
  • 41.Shi Y, Ye K, Wu H, Sun Y, Shi H, Huo K. Human SMAD4 is phosphorylated at Thr9 and Ser138 by interacting with NLK. Mol Cell Biochem. 2010;333:293–298. doi: 10.1007/s11010-009-0230-2. [DOI] [PubMed] [Google Scholar]
  • 42.Lazzarini R, Sorgentoni G, Caffarini M, Sayeed MA, Olivieri F, Di Primio R, Orciani M. New miRNAs network in human mesenchymal stem cells derived from skin and amniotic fluid. Int J Immunopathol Pharmacol. 2016;29:523–528. doi: 10.1177/0394632015610228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.He X, Liu Z, Peng Y, Yu C. MicroRNA-181c inhibits glioblastoma cell invasion, migration and mesenchymal transition by targeting TGF-β pathway. Biochem Biophys Res Commun. 2016;469:1041–1048. doi: 10.1016/j.bbrc.2015.12.021. [DOI] [PubMed] [Google Scholar]
  • 44.Stolzenburg LR, Wachtel S, Dang H, Harris A. microRNA-1343 attenuates pathways of fibrosis by targeting the TGF-β receptors. Biochem J. 2016;473:245–256. doi: 10.1042/BJ20150821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Shin JM, Park JH, Park IH, Lee HM. Pirfenidone inhibits transforming growth factor β1-induced extracellular matrix production in nasal polyp-derived fibroblasts. Am J Rhinol Allergy. 2015;29:408–413. doi: 10.2500/ajra.2015.29.4221. [DOI] [PubMed] [Google Scholar]
  • 46.Yamin M, Holbrook EH, Gray ST, Busaba NY, Lovett B, Hamilos DL. Profibrotic transforming growth factor beta 1 and activin A are increased in nasal polyp tissue and induced in nasal polyp epithelium by cigarette smoke and Toll-like receptor 3 ligation. Int Forum Allergy Rhinol. 2015;5:573–582. doi: 10.1002/alr.21516. [DOI] [PubMed] [Google Scholar]

Articles from Experimental and Therapeutic Medicine are provided here courtesy of Spandidos Publications

RESOURCES